Evaluation of Fattening Efficiency of Grazing Bulls through Panel Data Envelop Analysis

The purpose of this paper was to assess fattening efficiency changes in grazing bulls, using panel data envelop analysis in two periods of time. The panel data were compiled by DEAP 2.1, which included the results of a 3-year period from 38 private farms (beef farms) in cooperatives of credits and services. The farms were on prairie savannahs, located on 21.4831 latitude, and -77.3174 longitude, less than 300 meters above sea level, province of Camagüey, mideastern Cuba. The output variable was total sold kg (TSKG), and the input variables were cost of Norgold (CN), fuel kg per ha (FKGXHA), fuel kg per livestock unit (FKGXLU), and unit of human labor force (UHL), which were highly correlated to the output variable. Table 2 shows that technical efficiency (TE), pure efficiency (PEC), and scale sufficiency (SEC), underwent 0.2%, 0.4, and 0.5%, respectively, by the third year of fattening. Technological change (TC) between the second and third years rose to almost 14%, and the total productivity factor (TPF) spiked as farmers became more skilled and experienced, with a 4.9% increase in comparison to the first year, and 13.7% in the second year

Fattening Commercial Zebu with Grazing and Low Supplementation on Small Farms.

The aim of this paper was to describe and group grazing commercial Zebu bulls, with low supplementation. Forty-four beef-producing farms from several cooperatives of credits and services were studied. Their members are private farmers from Sibanicu, Camaguey, Cuba. The farms were visited for three years,  and official records were made of each farmer for these variables: resources, animals, management, production, and economy. The main statigraph for the variables were calculated. The  average  initial weight, final weight, weight gain, and production per ha were, 202.6; 371.6; 501; and 326.2 kg, during 339.7 fattening days, respectively. The principal component  analysis (PCA) showed  a Kaiser-Meyer-Olkin coefficient higher than 0.66, and a significant Bartlett  sphericity  coefficient (P < 0.01), with self-values above 1. The two groups were made using a BIETAPIC cluster analysis

Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis

BackgroundAndrogenetic alopecia (AGA) affects almost half the population, and several treatments intending to regenerate a normal scalp hair phenotype are used. This is the first study comparing treatment efficacy response and resistance using standardized continuous outcomes.ObjectiveTo systematically compare the relative efficacy of treatments used for terminal hair (TH) regrowth in women and men with AGA.MethodsA systematic literature review was conducted (from inception to August 11, 2021) to identify randomized, Placebo-controlled trials with ≥ 20 patients and reporting changes in TH density after 24 weeks. Efficacy was analyzed by sex at 12 and 24 weeks using Bayesian network meta-analysis (B-NMA) and compared to frequentist and continuous outcomes profiles.ResultsThe search identified 2,314 unique articles. Ninety-eight were included for full-text review, and 17 articles met the inclusion criteria for data extraction and analyses. Eligible treatments included ALRV5XR, Dutasteride 0.5 mg/day, Finasteride 1 mg/day, low-level laser comb treatment (LLLT), Minoxidil 2% and 5%, Nutrafol, and Viviscal. At 24 weeks, the B-NMA regrowth efficacy in TH/cm2 and significance (**) in women were ALRV5XR: 30.09**, LLLT: 16.62**, Minoxidil 2%: 12.13**, Minoxidil 5%: 10.82**, and Nutrafol: 7.32**, and in men; ALRV5XR: 21.03**, LLLT: 18.75**, Dutasteride: 18.37**, Viviscal: 13.23, Minoxidil 5%: 13.13**, Finasteride: 12.38, and Minoxidil 2%: 10.54. Two distinct TH regrowth response profiles were found; Continuous: ALRV5XR regrowth rates were linear in men and accelerated in women; Resistant: after 12 weeks, LLLT, Nutrafol, and Viviscal regrowth rates attenuated while Dutasteride and Finasteride plateaued; Minoxidil 2% and 5% lost some regrowth. There were no statistical differences for the same treatment between women and men. B-NMA provided more accurate, statistically relevant, and conservative results than the frequentist-NMA.ConclusionSome TH regrowth can be expected from most AGA treatments with less variability in women than men. Responses to drug treatments were rapid, showing strong early efficacy followed by the greatest resistance effects from flatlining to loss of regrowth after 12–16 weeks. Finasteride, Minoxidil 2% and Viviscal in men were not statistically different from Placebo. LLLT appeared more efficacious than pharmaceuticals. The natural product formulation ALRV5XR showed better efficacy in all tested parameters without signs of treatment resistance (see Graphical abstract).Systematic review registrationwww.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42021268040, identifier CRD42021268040

Paleoseismic evidence of the 1715 C.E earthquake on the Purgatorio Fault in Southern Peru: implications for seismic hazard in subduction zones

Active faults in the forearc of southern Peru pose a poorly understood hazard to the region. The Purgatorio Fault is a 60 km-long fault that extends between Moquegua and Tacna that has hosted several scarp-forming earthquakes over the last 6 ka. We present new measurements of the fault scarp geomorphology along the Purgatorio Fault and use dating of the stratigraphy within a new paleoseismic trench excavated across the fault to establish the chronology of scarp formation. We find that the most recent surface-rupturing earthquake on the Purgatorio Fault occurred sometime between 1630C.E and 1790C.E and had a moment magnitude (Mw) of ~7. We propose that this most recent surface-rupturing earthquake on the Purgatorio Fault was the 1715C.E earthquake recorded in the historical catalogue of the region, which was previously attributed to the megathrust offshore. Our results highlight the importance of establishing a paleoseismic record of onshore faults to differentiate between major megathrust and forearc earthquakes. Given the proximity of these shallow, onshore faults to coastal communities in Peru, the shallow earthquakes they generate may pose a severe, yet often overlooked, seismic hazard

Pequeñas unidades de ceba de Cebú comercial en pastoreo con baja suplementación.

El objetivo del trabajo fue describir y agrupar unidades de ceba de toros Cebú comerciales en pastoreo con baja suplementación. Se estudiaron 44 unidades de producción de carne bovina pertenecientes a cooperativas de crédito y servicio integradas por campesinos privados, del municipio Sibanicú, provincia Camagüey, Cuba. Se realizaron visitas a cada una de las unidades durante tres años y se tomaron los registros oficiales de cada productor para las variables: recursos, animales, manejo, producción y economía. Se calcularon los estadígrafos principales para estas variables. Los promedios de peso inicial, el peso final, la ganancia en peso y la producción por hectárea fueron: 202,6; 371,6; ,501 y 326,2 kg durante 339,7 días de ceba. Se obtuvieron 5 componentes principales rotados (Varimax). El análisis de componentes principales (ACP) mostró un coeficiente de Kaiser-Meyer-Olkin superior a 0,66 y un coeficiente de esfericidad de Bartlett significativo (P < 0,01) y autovalores mayores de 1. Se agruparon las unidades en dos grupos mediante un análisis de clúster bietápico.Small Fattening Units of Grazing Commercial Zebu with Low SupplementationABSTRACTThe objective of the work was to describe and group units of fattening of commercial Zebu bulls grazing with low supplementation. We studied 44 bovine meat production units  belonging to credit and service cooperatives by private farmers, in the municipality Sibanicú, Camagüey province, Cuba. Visits to each of the units were carried out for three years and took the official records of each producer for the variables: the resources, animals, management, production and economics. The major statisticians for this variables were calculated. The average initial weight, final weight, the weight gain and the production by hectare were 202,6; 371,6; 0,501 and 326,2 kg 339,7 days of fattening. Five principal components rotated (Varimax) were obtained. The Principal Analysis Components (PCA) showed a higher than 0,66 Kaiser-Meyer-Olkin coefficient, a coefficient of sphericity of significant Bartlett (P < 0,01) and eigenvalues greater than 1. Pooled units in two groups using two cluster analysis

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic